Newsfeeds - Spark Newswire

1 minute read

Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease

Today, 4:48 PM

Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ: RGLS) shares jumped after topline safety and Pharmacokinetic (PK) data from its Phase 1 single-ascending dose (SAD) trial of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD).

RGLS

6 minute read

Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:48 PM

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.

ADT

4 minute read

Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 4:48 PM

Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners.

ADT

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 4:48 PM

Gainers

ABVC

17 minute read

Earnings Scheduled For August 11, 2022

By Benzinga Insights

Today, 4:48 PM

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

AACG

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 4:48 PM

Gainers

AGLE

1 minute read

Regulus Therapeutics Announces On July 12, Sanofi Notified Co. Of Its Decision To Terminate Phase 2 Clinical Study Of Lademirsen For Treatment Of Alport Syndrome

By Benzinga Newsdesk

Today, 4:48 PM

https://www.sec.gov/ix?doc=/Archives/edgar/data/1505512/000119312522194935/d346170d8k.htm

RGLS

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 4:48 PM

Gainers

APRE

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 4:48 PM

AFIB

3 minute read

Recap of Tuesday’s Biotech Catalysts – End of the Day Summary

By Ragothaman Srinivasan

Today, 4:48 PM

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

ABBV